HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 3 (2006), Issue 3 (March)

1. Effects of perinatal HIV infection and associated risk factors on cognitive development among young children.
   Pediatrics, 117(3): 851-62. [Abstract] [Full-text]
2. A behavioral and cognitive profile of clinically stable HIV-infected children.
   Pediatrics, 117(3): 763-70. [Abstract] [Full-text]
3. Health, neurologic, and cognitive status of HIV-infected, long-surviving, and antiretroviral-naive Ugandan children.
   Pediatrics, 117(3): 729-40. [Abstract] [Full-text]
4. Reasons for testing and clinical and demographic profile of adolescents with non-perinatally acquired HIV infection.
   Pediatrics, 117(3): e468-75. [Abstract] [Full-text]
5. Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort.
   Pediatrics, 117(3): e528-36. [Abstract] [Full-text]
6. Long-term study of intraocular pressure changes in patients with human immunodeficiency virus treated with highly active antiretroviral therapy.
   Ophthalmology, 113(3): 451-5. [Abstract] [Full-text]
7. CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: is it associated with age at initiation?
   J Infect Dis, 193(7): 954-62. [Abstract] [Full-text]
8. Inhibitory effects of archetypical nucleic acid ligands on the interactions of HIV-1 nucleocapsid protein with elements of Psi-RNA.
   Nucleic Acids Res, 34(5): 1305-16. [Abstract] [Full-text]
9. The global impact of scaling up HIV/AIDS prevention programs in low- and middle-income countries.
   Science, 311(5766): 1474-6. [Abstract] [Full-text]
10. CD4+ T cell receptor repertoire perturbations in HIV-1 infection: association with plasma viremia and disease progression.
    Clin Immunol, 119(1): 95-102. [Abstract] [Full-text]
11. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.
    Lancet, 367(9513): 817-24. [Abstract] [Full-text]
12. Better quality of life with neuropsychological improvement on HAART.
    Health Qual Life Outcomes, 4: 11. [Abstract] [Full-text]
13. Pyridine N-oxide derivatives inhibit viral transactivation by interfering with NF-kappaB binding.
    Biochem Pharmacol, 71(8): 1122-35. [Abstract] [Full-text]
14. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.
    Arch Intern Med, 166(5): 521-8. [Abstract] [Full-text]
15. Whole body leucine flux in HIV-infected patients treated with or without protease inhibitors.
    Am J Physiol Endocrinol Metab, 290(4): E685-93. [Abstract] [Full-text]
16. Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele.
    J Virol, 80(7): 3684-91. [Abstract] [Full-text]
17. Functional central polypurine tract provides downstream protection of the human immunodeficiency virus type 1 genome from editing by APOBEC3G and APOBEC3B.
    J Virol, 80(7): 3679-83. [Abstract] [Full-text]
18. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1.
    J Virol, 80(7): 3617-23. [Abstract] [Full-text]
19. Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate.
    J Virol, 80(7): 3607-16. [Abstract] [Full-text]
20. Human chromosome 2 carries a gene required for production of infectious human immunodeficiency virus type 1.
    J Virol, 80(7): 3406-15. [Abstract] [Full-text]
21. Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion.
    J Virol, 80(7): 3249-58. [Abstract] [Full-text]
22. Acetylated Tat regulates human immunodeficiency virus type 1 splicing through its interaction with the splicing regulator p32.
    J Virol, 80(7): 3189-204. [Abstract] [Full-text]
23. R5 and X4 HIV envelopes induce distinct gene expression profiles in primary peripheral blood mononuclear cells.
    Proc Natl Acad Sci U S A, 103(10): 3746-51. [Abstract] [Full-text]
24. Clonal population structure and genetic diversity of Candida albicans in AIDS patients from Abidjan (Côte d'Ivoire).
    Proc Natl Acad Sci U S A, 103(10): 3663-8. [Abstract] [Full-text]
25. Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.
    J Med Chem, 49(6): 2037-48. [Abstract] [Full-text]
26. Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities, and mechanism of action.
    J Med Chem, 49(6): 1939-45. [Abstract] [Full-text]
27. HIV-related sexual behaviour among migrants and non-migrants in a rural area of China: role of rural-to-urban migration.
    Public Health, 120(4): 339-45. [Abstract] [Full-text]
28. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment.
    Lancet, 367(9514): 926-37. [Abstract] [Full-text]
29. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study.
    J Clin Oncol, 24(9): 1389-94. [Abstract] [Full-text]
30. Elevated incidence of lung cancer among HIV-infected individuals.
    J Clin Oncol, 24(9): 1383-8. [Abstract] [Full-text]
31. Immune responses and HIV: a little order from the chaos.
    J Exp Med, 203(3): 501-3. [Abstract] [Full-text]
32. Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus.
    J Exp Med, 203(3): 529-39. [Abstract] [Full-text]
33. Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine.
    J Exp Med, 203(3): 607-17. [Abstract] [Full-text]
34. Retroviral DNA integration: reaction pathway and critical intermediates.
    EMBO J, 25(6): 1295-304. [Abstract] [Full-text]
35. Symptomatic hyperlactataemia precipitated by the addition of tetracycline to combination antiretroviral therapy.
    Lancet Infect Dis, 6(4): 249-52. [Abstract] [Full-text]
36. Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy.
    Lancet Infect Dis, 6(4): 215-25. [Abstract] [Full-text]
37. CD8 T cell effector maturation in HIV-1-infected children.
    Virology, 347(1): 117-26. [Abstract] [Full-text]
38. Waiting times for the appearance of cytotoxic T-lymphocyte escape mutants in chronic HIV-1 infection.
    Virology, 347(1): 140-6. [Abstract] [Full-text]
39. Replicative fitness of CCR5-using and CXCR4-using human immunodeficiency virus type 1 biological clones.
    Virology, 347(1): 65-74. [Abstract] [Full-text]
40. Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.
    Virology, 347(1): 36-51. [Abstract] [Full-text]
41. Commercial sex work and risk of HIV infection among young drug-injecting men who have sex with men in San Francisco.
    Sex Transm Dis, 33(4): 228-34. [Abstract] [Full-text]
42. Association between 'safer sex fatigue' and rectal gonorrhea is mediated by unsafe sex with casual partners among HIV-positive homosexual men.
    Sex Transm Dis, 33(4): 201-8. [Abstract] [Full-text]
43. Unsafe sexual behavior and correlates of risk in a probability sample of men who have sex with men in the era of highly active antiretroviral therapy.
    Sex Transm Dis, 33(4): 250-5. [Abstract] [Full-text]
44. The C-terminal 26-residue peptide of serpin A1 is an inhibitor of HIV-1.
    Biochem Biophys Res Commun, 343(2): 617-22. [Abstract] [Full-text]
45. Cerebral metabolites in HIV-infected children followed for 10 months with 1H-MRS.
    Neurology, 66(6): 874-9. [Abstract] [Full-text]
46. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort.
    Neurology, 66(6): 867-73. [Abstract] [Full-text]
47. Caudate blood flow and volume are reduced in HIV+ neurocognitively impaired patients.
    Neurology, 66(6): 862-6. [Abstract] [Full-text]
48. Is skin biopsy a predictor of transition to symptomatic HIV neuropathy? A longitudinal study.
    Neurology, 66(6): 857-61. [Abstract] [Full-text]
49. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report.
    Neurology, 66(6): 919-21. [Abstract] [Full-text]
50. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial.
    Cancer, 106(7): 1560-8. [Abstract] [Full-text]
51. Human papillomavirus (HPV) detection among human immunodeficiency virus-infected pregnant Thai women: implications for future HPV immunization.
    Sex Transm Dis, 33(4): 259-64. [Abstract] [Full-text]
52. Associations between substance use and sexual risk among very young men who have sex with men.
    Sex Transm Dis, 33(4): 265-71. [Abstract] [Full-text]
53. Hepatitis C virus protease gene diversity in patients coinfected with human immunodeficiency virus.
    J Virol, 80(8): 4196-9. [Abstract] [Full-text]
54. Trim-cyclophilin A fusion proteins can restrict human immunodeficiency virus type 1 infection at two distinct phases in the viral life cycle.
    J Virol, 80(8): 4061-7. [Abstract] [Full-text]
55. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events.
    J Virol, 80(8): 4017-25. [Abstract] [Full-text]
56. Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.
    J Virol, 80(8): 3732-42. [Abstract] [Full-text]
57. Evidence for a functional link between uncoating of the human immunodeficiency virus type 1 core and nuclear import of the viral preintegration complex.
    J Virol, 80(8): 3712-20. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.